Prolonged follow‐up on lenalidomide‐based treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma)—Real‐world data from the Medical University of Vienna

Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa‐associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Hematol Oncol
Hlavní autoři: Kiesewetter, Barbara, Lamm, Wolfgang, Neuper, Ortrun, Mayerhoefer, Marius E., Simonitsch‐Klupp, Ingrid, Raderer, Markus
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Original Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6899635/
https://ncbi.nlm.nih.gov/pubmed/31283840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hon.2647
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky